A Perspective on the Whole Foods Decision: Would the Most Important Evidence Please Stand Up?
Michael Bernstein, Deborah Feinstein, Apr 24, 2008
In the old game show, To Tell the Truth, panelists tried to convince the audience that they were the one associated with a particular story. They had to weave facts and details into the story to make it sound like the events had happened to them. The audience had to try to figure out which facts were likely to be consistent with the actual story. At the end, the host asked the real person associated with the story to stand up. Analyzing a merger has many similarities to this old game show. While hopefully no one in a merger analysis is actively trying to mislead, the decision makers must still sort through a plethora of facts to determine which are consistent with a theory that would condemn a merger versus a theory that would clear a merger. This is a particularly difficult exercise in a retail merger. There are no customers to interview and there are no customers documents from which one can glean how they might behave in the event of changes in the competitive environment. Which facts are meaningful and which are simply details that serve only to obscure the story? Which facts should be given weight and which should be ignored? And, how much weight should documentary and testimonial evidence be given as compared to economic evidence? An examination of these issues in the Whole Foods matter shows that what the U.S. Federal Trade Commission (FTC) and the district court thought the evidence showed, and what weight to give various evidence, differed so significantly that they reached entirely different conclusions about the matter.
Featured News
DOJ Prosecutors Advise Against Criminal Charges in Live Nation Antitrust Probe
Dec 17, 2025 by
CPI
Supreme Court Closes Door on REX Antitrust Case Against Realtors Group
Dec 17, 2025 by
CPI
PepsiCo and Walmart Face Federal Lawsuit Alleging Long-Running Price-Fixing Scheme
Dec 17, 2025 by
CPI
Utah Reaches Antitrust Settlement With Sandoz Over Generic Drug Pricing
Dec 17, 2025 by
CPI
China Regulator Flags ‘Lowest-Price’ Demands as Potential Antitrust Violations
Dec 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi